Global Insulin Glargine Market Study 2015-2025, by Segment (Single Dose Vial, Pre-filled Syringe), by Market (Treat type 1 diabetes, Treat type 2 diabetesPre-filled Syringe), by Company (Sanofi-Aventis, Ganlee, Biocon)

ReportPage
Report ID
45062
Published Date
24-Sep
No of Report Page
66
Report Category
Pharmaceuticals and Healthcare
Editor's Rating
US $3,600.00
US $3,600.00
US $1,800.00

  • Report Details

    Snapshot
    Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a “peakless” profile (according to the insulin glargine package insert).
    The global Insulin

    More...
  • Table Of Content

    Table of Content
    1 Industry Overview
    1.1 Insulin Glargine Industry
    1.1.1 Overview
    1.1.2 Products of Major Companies
    1.2 Market Segment
    1.2.1 Industry Chain
    1.2.2 Consumer Distribution
    1.3 Price & Cost Overview
    2 Insulin Glargine Market by Type
    2.1 By Type
    2.1.1 Single Dose Vial
    2.1.2 Pre-filled Syringe
    2.2 Market Size by Type
    2.

    More...
  • Inquiry Before Buying
    Inquiry Before Buying -
  • Request Sample
    Request For Sample